Aspergillus spp. are ubiquitous and cause severe infections in immunocompromised
patients. Less is known about its incidence and prognosis in patients with HIV/AIDS. We …

Chronic pulmonary aspergillosis (CPA) refers to a number of clinical syndromes resulting
from the presence and local proliferation of Aspergillus organisms in the lungs of patients …

Chronic pulmonary aspergillosis (CPA) may mimic pulmonary tuberculosis (PTB). The two
diseases are clinically indistinguishable and may result in CPA misdiagnosed as PTB or …

Background: It is of utmost importance to monitor any change in the epidemiology of fungal
diseases that may arise from a change in the number of the at-risk population or the …

When Aspergillus, an ubiquitous, saprophytic fungus, is detected in respiratory tract
specimens collected from chronic respiratory disease patients, it is important to determine …

Introduction Chronic pulmonary aspergillosis (CPA) is a debilitating disease estimated to
affect over 3 million people worldwide. Pulmonary tuberculosis (PTB) is the most significant …

Chronic pulmonary aspergillosis (CPA) often occurs in patients that have been previously
treated for pulmonary tuberculosis (PTB). A limited number of studies have looked at the …

Background Both pulmonary tuberculosis (PTB) and chronic pulmonary aspergillosis (CPA)
significantly affect health-related quality of life (HR-QoL). We aimed to determine the impact …

Purpose Voriconazole, a first-line therapeutic agent for chronic pulmonary aspergillosis, is
metabolized by the cytochrome 450 enzymes, specifically CYP2C19 and CYP3A4 …

Background Chronic pulmonary aspergillosis (CPA) is known to complicate patients with
post‐tubercular lung disease. However, some evidence suggests that CPA might co‐exist in …